Teppei Yamaguchi

743 total citations
43 papers, 458 citations indexed

About

Teppei Yamaguchi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Teppei Yamaguchi has authored 43 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Teppei Yamaguchi's work include Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Lung Cancer Research Studies (9 papers). Teppei Yamaguchi is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Lung Cancer Research Studies (9 papers). Teppei Yamaguchi collaborates with scholars based in Japan and United States. Teppei Yamaguchi's co-authors include Yoshitsugu Horio, Junichi Shimizu, Toyoaki Hida, Yoshitaka Inaba, Takaaki Hasegawa, Yasushi Yatabe, Kazuyoshi Imaizumi, Yasuhiro Gotô, Sumito Isogai and Sakurako Uozu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Teppei Yamaguchi

37 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Teppei Yamaguchi Japan	12	299	201	32	32	29	43	458
Eisuke Matsuda Japan	8	166 0.6×	180 0.9×	45 1.4×	10 0.3×	5 0.2×	30	421
Kenji Sawa Japan	11	221 0.7×	138 0.7×	21 0.7×	11 0.3×	4 0.1×	40	312
Ladislav Jebavý Czechia	14	57 0.2×	199 1.0×	31 1.0×	26 0.8×	17 0.6×	52	517
Michela Salvatici Italy	10	112 0.4×	432 2.1×	20 0.6×	46 1.4×	46 1.6×	17	835
Sheng‐Hsuan Chien Taiwan	13	51 0.2×	92 0.5×	45 1.4×	62 1.9×	18 0.6×	39	382
Yongmei Liu China	14	336 1.1×	174 0.9×	84 2.6×	14 0.4×	9 0.3×	31	684
Faiz M. Khan United States	11	180 0.6×	56 0.3×	35 1.1×	18 0.6×	21 0.7×	19	399
K. Dardoufas Greece	13	366 1.2×	148 0.7×	32 1.0×	20 0.6×	14 0.5×	25	581
Ju Won Lee South Korea	9	195 0.7×	28 0.1×	29 0.9×	12 0.4×	18 0.6×	18	335
Dimitrios X. G. Divaris Canada	8	262 0.9×	143 0.7×	68 2.1×	39 1.2×	42 1.4×	10	482

Countries citing papers authored by Teppei Yamaguchi

Since Specialization

Citations

This map shows the geographic impact of Teppei Yamaguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teppei Yamaguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teppei Yamaguchi more than expected).

Fields of papers citing papers by Teppei Yamaguchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teppei Yamaguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teppei Yamaguchi. The network helps show where Teppei Yamaguchi may publish in the future.

Co-authorship network of co-authors of Teppei Yamaguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Teppei Yamaguchi. A scholar is included among the top collaborators of Teppei Yamaguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teppei Yamaguchi. Teppei Yamaguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hasegawa, Takaaki, Toru Okuyama, Takehiro Uemura, et al.. (2024). Unrealistic expectations and disclosure of incurability in patients with non-small cell lung cancer. Supportive Care in Cancer. 32(7). 421–421.

Horinouchi, Hidehito, Isao Yokota, Teppei Yamaguchi, et al.. (2024). Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056). Cancer Science. 115(11). 3705–3717. 1 indexed citations

Fujiwara, Yutaka, Katsuhiro Masago, Teppei Yamaguchi, et al.. (2024). Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report. SHILAP Revista de lepidopterología. 17(1). 942–949.

Yamaguchi, Teppei, et al.. (2024). Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis. BMC Cancer. 24(1). 842–842. 3 indexed citations

Fujiwara, Yutaka, Kazuhiro Shimomura, Teppei Yamaguchi, et al.. (2024). The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review. Frontiers in Oncology. 14. 1419256–1419256. 1 indexed citations

Yamaguchi, Teppei, Katsuhiro Masago, Eiichi Sasaki, et al.. (2023). EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC. Cancer Genetics. 280-281. 13–16.

Hasegawa, Takaaki, Toru Okuyama, Yoshinobu Matsuda, et al.. (2023). Elements of End-of-Life Discussions Associated With Patients’ Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer. The Oncologist. 29(2). e282–e289. 3 indexed citations

Morise, Masahiro, Kentaro Ito, Osamu Hataji, et al.. (2023). Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial. EClinicalMedicine. 66. 102303–102303. 6 indexed citations

Toyozawa, Ryo, Kota Itahashi, Yutaka Fujiwara, et al.. (2021). 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). Annals of Oncology. 32. S1002–S1003. 4 indexed citations

10.

Yamaguchi, Teppei, Hiroshi Yatsuya, Yasuhiro Gotô, et al.. (2021). Predictive risk factors for pneumothorax after transbronchial biopsy using endobronchial ultrasonography with a guide sheath. BMC Pulmonary Medicine. 21(1). 181–181. 1 indexed citations

11.

Yamaguchi, Teppei, Junichi Shimizu, Yuko Oya, Yoshitsugu Horio, & Toyoaki Hida. (2021). Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information. Case Reports in Oncology. 14(2). 886–891. 11 indexed citations

12.

Yamaguchi, Teppei, Junichi Shimizu, Takaaki Hasegawa, et al.. (2021). Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer. 21(1). 924–924. 22 indexed citations

13.

Yamaguchi, Teppei, Junichi Shimizu, Takaaki Hasegawa, et al.. (2018). Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. Lung Cancer. 125. 212–217. 111 indexed citations

14.

Uemura, Takehiro, Tatsuya Yoshida, Teppei Yamaguchi, et al.. (2018). Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment. Anticancer Research. 38(9). 5231–5237. 16 indexed citations

15.

Yamaguchi, Teppei, Kazuo Sakurai, Makoto Kuroda, Kazuyoshi Imaizumi, & Toyoaki Hida. (2017). Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer. Case Reports in Oncology. 10(3). 802–808. 4 indexed citations

16.

Yamaguchi, Teppei, Yasuhiro Gotô, Tomoya Horiguchi, et al.. (2016). Clinical features of primary lung cancer presenting as pulmonary consolidation mimicking pneumonia. SHILAP Revista de lepidopterología. 5 indexed citations

17.

Yamaguchi, Teppei, Sakurako Uozu, Sumito Isogai, et al.. (2016). Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis. Supportive Care in Cancer. 25(4). 1215–1220. 16 indexed citations

18.

Yatsuya, Hiroshi, Naoki Yamamoto, Teppei Yamaguchi, et al.. (2015). Bronchus sign on thin-section computed tomography is a powerful predictive factor for successful transbronchial biopsy using endobronchial ultrasound with a guide sheath for small peripheral lung lesions: a retrospective observational study. BMC Medical Imaging. 15(1). 21–21. 76 indexed citations

19.

Tsuzuki, M, Fumio Maruyama, Teruo Ino, et al.. (1997). Proliferative effects of several hematopoietic growth factors on acute myelogenous leukemia cells and correlation with treatment outcome. Leukemia. 11(12). 2125–2130. 17 indexed citations

20.

Chung, Jin Hoon, C. W. Song, Teppei Yamaguchi, & Joseph Tabachnick. (1972). Effect of Anti-Inflammatory Compounds on β-Irradiation Induced Radiodermatitis. Dermatology. 144(2). 97–107. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact